



HAL
open science

Prevalence of antibodies to swine influenza viruses in humans with occupational exposure to pigs, Thuringia, Germany, 2008-2009

Andi Krumbholz, Jeannette Lange, Ralf Dürrwald, Heike Hoyer, Stefan Bengsch, Peter Wutzler, Roland Zell

► **To cite this version:**

Andi Krumbholz, Jeannette Lange, Ralf Dürrwald, Heike Hoyer, Stefan Bengsch, et al.. Prevalence of antibodies to swine influenza viruses in humans with occupational exposure to pigs, Thuringia, Germany, 2008-2009. *Journal of Medical Virology*, 2010, 82 (9), pp.1617. 10.1002/jmv.21869. hal-00556041

HAL Id: hal-00556041

<https://hal.science/hal-00556041>

Submitted on 15 Jan 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Prevalence of antibodies to swine influenza viruses in humans with occupational exposure to pigs, Thuringia, Germany, 2008-2009

| | |
|-------------------------------|--|
| Journal: | <i>Journal of Medical Virology</i> |
| Manuscript ID: | JMV-09-1647.R2 |
| Wiley - Manuscript type: | Research Article |
| Date Submitted by the Author: | 28-Apr-2010 |
| Complete List of Authors: | Krumbholz, Andi; Jena University Hospital, Dept. of Virology and Antiviral Therapy Lange, Jeannette; Jena University Hospital, Dept. of Virology and Antiviral Therapy Dürwald, Ralf; IDT Biologika GmbH, Dept. Research and Development Hoyer, Heike; Jena University Hospital, Dept. of Medical Statistics and Documentation Bensch, Stefan; Jena University Hospital, Dept. of Transfusion Medicine Wutzler, Peter; Jena University Hospital, Dept. of Virology and Antiviral Therapy Zell, Roland; Friedrich Schiller University, Institut of Virology and Antiviral Therapy |
| Keywords: | porcine influenza virus, zoonotic infection, virus neutralisation assay, hemagglutination-inhibition assay, occupational exposure |
| | |



TABLE I. Composition of Study and Control Groups

| | Study group | | | | | | | | | | | | Total, no (%) |
|----------------------------------|-----------------|-------------------|-----------------------------------|--------------------|-------------------|-----------------|---|-----------------------------|--------------------------|------------------|------------|-----------|------------------|
| | Gender | | Mean age, years (\pm SD) | Age groups, no (%) | | | Flu-vaccination history, no (%) | | Exposure to pigs, no (%) | | | n.a. | |
| | No males (%) | No females (%) | | <40 years | 40 to 50 years | \geq 50 years | No vaccination or no data available | At least one vaccination | 0 to 5 years | 6 to 10 years | > 10 years | | |
| Pig farmers | 19 (41.3%) | 27 (58.7%) | 45.8 (\pm 9.6) | 10 (21.7%) | 19 (41.3%) | 17 (37.0%) | 21 (45.6%) | 25 (54.3%) | 5 (10.9%) | 5 (10.9%) | 28 (60.9%) | 8 (17.3%) | 46 (100%) |
| Slaughterers/ meat inspectors | 40 (80.0%) | 10 (20.0%) | 41.8 (\pm 11.7) | 18 (36.0%) | 19 (38.0%) | 13 (26.0%) | 31 (62%) | 19 (38%) | 10 (20%) | 8 (16%) | 32 (64%) | 0 (0%) | 50 (100%) |
| Veterinarians | 13 (59.1%) | 9 (40.9%) | 48.3 (\pm 9.2) | 4 (18.2%) | 6 (27.3%) | 12 (54.5%) | 14 (63.6%) | 8 (36.4%) | 2 (9.1%) | 2 (9.1%) | 18 (81.8%) | 0 (0%) | 22 (100%) |
| Total | 72 (61.0%) | 46 (39.0%) | 44.6(\pm 10.7) | 32 (27.1%) | 44 (37.3%) | 42 (35.5%) | 66 (55.9%) | 52 (44.1%) | 17 (14.4%) | 15 (12.7%) | 78 (66.1%) | 8 (6.8%) | 118 (100%) |
| | Control group | | | | | | | | | | | | Total, no (%) |
| | Gender | | Mean age, years (\pm SD) | Age groups, no (%) | | | Flu-vaccination history, no (%) | | Exposure to pigs, no (%) | | | - | |
| | No males (%) | No females (%) | | <40 years | 40 to 50 years | \geq 50 years | No vaccination or no data available | At least one vaccination | - | - | - | | |
| Blood donors | 72 (61.0%) | 46 (39.0%) | 43.8(\pm 11.8) | 32 (27.1%) | 44 (37.3%) | 42 (35.5%) | 53 (44.9%) | 65 (55.1%) | - | - | - | - | 118 (100%) |

TABLE II. Antibody Titers of Proband and Control Sera Conspicuous in HI Assay*

| Proband characteristics | | | | | Reciprocal geometric mean titers of hemagglutination inhibition (HI) and neutralisation tests (NT) | | | | | | | | | | | |
|-------------------------|--------|------------|-------------------------|-------------------------------|--|--------|---------------------|---------|---------------------|---------|---------------------|--------|---------------------|---------|---------------------|--------|
| Serum | Gender | Age, years | Flu vaccination history | Time of pig exposition, years | swH1N1 ¹ | | huH1N1 ² | | swH1N2 ³ | | huH1N2 ⁴ | | swH3N2 ⁵ | | huH3N2 ⁶ | |
| | | | | | HAHT | NT | HAHT | NT | HAHT | NT | HAHT | NT | HAHT | NT | HAHT | NT |
| S2 | m | 40 | annual vacc. | 1.5 | 3.79 | <20 | 80.00 | 40.00 | 160.00 | 40.00 | 80.00 | <20 | 29.39 | <20 | 160.00 | <20 |
| S6 | m | 38 | no vaccination | 20 | 20.00 | 26.26 | 9.28 | <20 | 34.29 | 28.28 | 50.40 | 20.00 | 80.00 | 2031.87 | 63.50 | 56.57 |
| S8 | m | 49 | no vaccination | 33 | 29.39 | 20.00 | - | - | 65.63 | 20.00 | - | - | 226.27 | 89.80 | - | - |
| S12 | m | 38 | 1 vaccination | 21 | 12.95 | 20.00 | 40.00 | 28.28 | 40.00 | 40.00 | 50.40 | 80.00 | 137.16 | 358.19 | 31.75 | 20.00 |
| S21 | m | 40 | 1 vaccination | 25 | 74.07 | 226.27 | 20.00 | <20 | 46.66 | 160.00 | 50.40 | 40.00 | 46.66 | 640.00 | 20.00 | 56.57 |
| S22 | m | 22 | no vaccination | 2 | 37.03 | 26.26 | 1015.94 | 905.10 | 160.00 | 1612.70 | 806.35 | 640.00 | 93.32 | 3620.39 | 80.00 | 40.00 |
| S24 | m | 40 | no vaccination | 25 | 46.66 | 570.18 | 20.00 | <20 | 40.00 | 359.19 | 40.00 | 20.00 | 148.14 | 3225.40 | 20.00 | 113.14 |
| S47 | m | 39 | no vaccination | 22 | 1.95 | <20 | 25.20 | <20 | 20.00 | 80.00 | 80.00 | - | 74.07 | 201.59 | 80.00 | 80.00 |
| PF16 | f | 49 | 1 vaccination | 33 | 31.75 | 20.00 | 1280.00 | 1280.00 | 34.29 | <20 | 403.17 | 80.00 | 108.86 | 570.18 | 1612.70 | 320.00 |
| PF18 | f | 39 | annual vacc. | 21 | 31.75 | 63.50 | 403.17 | 905.10 | 148.14 | 507.97 | 320.00 | 452.55 | 23.33 | 226.27 | 403.17 | 320.00 |
| PF22 | m | 38 | no vaccination | 15 | 9.28 | 20.00 | 7.37 | <20 | 40.00 | <20 | 40.00 | 40.00 | 80.00 | 1015.94 | 80.00 | 56.57 |
| PF43 | m | 55 | 1 vaccination | 39 | 2.71 | 40.00 | 80.00 | 80.00 | 117.58 | 507.97 | 40.00 | 320.00 | 13.99 | 160.00 | 63.50 | 113.14 |
| PF44 | m | 49 | annual vacc. | 1 | 2.71 | 20.00 | 40.00 | 40.00 | 27.22 | 56.57 | 40.00 | 56.57 | 93.32 | 570.18 | 160.00 | 40.00 |
| V1 | f | 35 | annual vacc. | 10 | 19.51 | 56.57 | 50.40 | 40.00 | 137.16 | 806.35 | 80.00 | 320.00 | 58.79 | 226.27 | 80.00 | 56.57 |
| V8 | f | 45 | annual vacc. | 20 | 8.60 | 20.00 | 40.00 | 28.28 | 30.97 | 56.57 | 50.40 | 80.00 | 126.99 | 1015.94 | 100.79 | 80.00 |
| V10 | f | 50 | no vaccination | 22 | 25.20 | 20.00 | 25.20 | <20 | 31.75 | 28.28 | 25.20 | 20.00 | 68.58 | 201.59 | 20.00 | 28.28 |
| V14 | m | 41 | no vaccination | 14 | 7.96 | 20.00 | 20.00 | <20 | 34.29 | <20 | 25.20 | 40.00 | 86.40 | 1436.75 | 50.40 | 40.00 |
| V18 | m | 43 | 1 vaccination | 15 | 10.03 | 20.00 | 50.40 | 40.00 | 100.79 | 201.59 | 25.20 | 40.00 | 93.32 | 507.97 | 31.75 | <20 |
| C7 | f | 21 | no vaccination | - | 10.26 | <20 | 403.17 | 452.55 | 86.40 | 44.90 | 100.79 | 28.28 | 5.70 | <20 | 160.00 | 113.14 |
| C10 | m | 22 | annual vacc. | - | 7.37 | <20 | 160.00 | 113.14 | 86.40 | 56.57 | 160.00 | 56.57 | 5.70 | <20 | 160.00 | 113.14 |
| C24 | m | 29 | no vaccination | - | 11.99 | <20 | 403.17 | 452.55 | 86.40 | 43.26 | 100.79 | <20 | 50.40 | 25.20 | 20.00 | 226.27 |
| C29 | m | 31 | at least 2 vacc. | - | 10.28 | <20 | 63.50 | 56.57 | 29.39 | <20 | 25.20 | 40.00 | 80.00 | 35.64 | 63.50 | 160.00 |
| C64 | m | 29 | at least 2 vacc. | - | 11.10 | <20 | 100.79 | 56.57 | 80.00 | 40.00 | 160.00 | <20 | 50.40 | 25.20 | 63.50 | 80.00 |
| C78 | m | 26 | 1 vaccination | - | 3.79 | <20 | 63.50 | <20 | 100.79 | 44.90 | 126.99 | 40.00 | 14.34 | <20 | 100.79 | 40.00 |
| C86 | m | 57 | no vaccination | - | 1.95 | <20 | 2.71 | <20 | 5.28 | <20 | 20.00 | <20 | 80.00 | 56.57 | 31.75 | <20 |
| C88 | m | 46 | 1 vaccination | - | 19.51 | <20 | 100.79 | <20 | 108.86 | 71.27 | 126.99 | 56.57 | 37.03 | 22.45 | 160.00 | 80.00 |
| C102 | m | 45 | no vaccination | - | 14.34 | <20 | 20.00 | 40.00 | 40.00 | <20 | 9.28 | <20 | 86.40 | 35.64 | 20.00 | <20 |
| C115 | f | 44 | at least 2 vacc. | - | 25.20 | <20 | 201.59 | 160.00 | 86.40 | 89.80 | 160.00 | 80.00 | 63.50 | 56.57 | 63.50 | 113.14 |
| C119 | f | 43 | 1 vaccination | - | 7.37 | <20 | 25.20 | <20 | 11.99 | <20 | 20.00 | <20 | 126.99 | 63.50 | 31.75 | <20 |
| C123 | f | 42 | at least 2 vacc. | - | 15.49 | <20 | 80.00 | 56.57 | 34.29 | <20 | 40.00 | 28.28 | 86.40 | 28.28 | 160.00 | 113.14 |

* sera with HI titers ≥ 80 or 4-fold increase of HI titer relative to group-specific mean titers¹ swH1N1 strains: A/swine/Belzig/2/2001, A/swine/Haselünne/IDT2617/2003, A/sw/Bad Griesbach/IDT5604/2006² huH1N1 strain: A/New Caledonia/20/1999³ swH1N2 strains: A/swine/Bakum/1832/2000, A/swine/Waltersdorf/IDT2527/2003, A/swine/Gudensberg/IDT2930/2004⁴ huH1N2 strain: A/Baden Württemberg/20/2003⁵ swH3N2 strains: A/swine/Bakum/1769/2003, A/swine/Bissendorf/IDT1864/2003, A/swine/Herzlake/IDT5336/2006⁶ huH3N2 strain: A/Berlin/1/2003

TABLE III. Summary of HI Assays

| Virus | Titer | Number of sera | | | | Control group (n=118) |
|---------------------------------|-----------|---------------------|--------------------|----------------------|---------------|--------------------------|
| | | Study group (n=118) | | | | |
| | | Slaughterers (n=50) | Pig farmers (n=46) | Veterinarians (n=22) | Total (n=118) | |
| swH1N1 | <20 | 35 | 19 | 19 | 84 | 104 |
| | 20 to <40 | 13 | 3 | 3 | 32 | 14 |
| | 40 to <80 | 2 | - | - | 2 | - |
| | ≥80 | - | - | - | - | - |
| swH1N2 | <20 | 14 | 7 | 3 | 24 | 32 |
| | 20 to <40 | 20 | 31 | 15 | 66 | 54 |
| | 40 to <80 | 14 | 6 | 2 | 22 | 25 |
| | ≥80 | 2 | 2 | 2 | 6 | 7 |
| swH3N2 | <20 | 23 | 13 | 10 | 46 | 46 |
| | 20 to <40 | 13 | 29 | 5 | 47 | 38 |
| | 40 to <80 | 9 | 1 | 4 | 14 | 29 |
| | ≥80 | 5 | 3 | 3 | 11 | 5 |
| huH1N1* | <20 | 8 | 5 | - | 13 | 18 |
| | 20 to <40 | 29 | 30 | 16 | 75 | 54 |
| | 40 to <80 | 4 | 3 | 4 | 11 | 22 |
| | ≥80 | 8 | 8 | 2 | 18 | 24 |
| huH1N2* | <20 | - | 4 | 7 | 11 | 24 |
| | 20 to <40 | 16 | 17 | 10 | 43 | 52 |
| | 40 to <80 | 20 | 18 | 4 | 42 | 20 |
| | ≥80 | 13 | 7 | 1 | 21 | 22 |
| huH3N2* | <20 | 3 | 2 | - | 5 | 8 |
| | 20 to <40 | 16 | 12 | 11 | 39 | 56 |
| | 40 to <80 | 11 | 8 | 6 | 25 | 23 |
| | ≥80 | 19 | 24 | 5 | 48 | 31 |
| A/Port Chalmers/1/73 (H3N2)* | <20 | 1 | 2 | 1 | 4 | 1 |
| | 20 to <40 | 26 | 23 | 10 | 59 | 54 |
| | 40 to <80 | 11 | 14 | 2 | 27 | 36 |
| | ≥80 | 11 | 7 | 9 | 27 | 27 |
| A/Chile/1/83 (H1N1)* | <20 | - | 6 | 2 | 8 | 6 |
| | 20 to <40 | 33 | 27 | 15 | 75 | 88 |
| | 40 to <80 | 14 | 12 | 3 | 29 | 18 |
| | ≥80 | 2 | 1 | 2 | 5 | 6 |

* Study group comprised 117 sera

TABLE IV. Prevalences of Antibodies Against Porcine Influenza Viruses

| Group | H1N1 | | H1N2 | | H3N2 | |
|-----------------------------|---------------------|----------------------|---------------------|----------------------|---------------------|----------------------|
| | Prevalence (no., %) | 95% CI (%), p-value* | Prevalence (no., %) | 95% CI (%), p-value* | Prevalence (no., %) | 95% CI (%), p-value* |
| <i>Slaughterers</i> (n=50) | 2 of 50, 4.0 | (0.4, 13.8), – | 3 of 50, 6.0 | (1.2, 16.6), 0.025 | 7 of 50, 14.0 | (5.8, 26.8), <0.001 |
| <i>Pig farmers</i> (n=46) | 0 of 46, 0.0 | (0.0, 7.8), – | 2 of 46, 4.3 | (0.5, 14.9), 0.077 | 4 of 46, 8.7 | (2.4, 20.8), 0.006 |
| <i>Veterinarians</i> (n=22) | 0 of 22, 0.0 | (0.0, 15.5), – | 2 of 22, 9.1 | (1.1, 29.2), 0.024 | 5 of 22, 22.7 | (7.8, 45.4), <0.001 |
| Exposed group (n=118) | 2 of 118, 1.7 | (0.0, 6.0), – | 7 of 118, 5.9 | (2.4, 11.9), 0.01 | 16 of 118, 13.6 | (7.9, 21.1), <0.001 |
| Control group (n=118) | 0 of 118, 0.0 | (0.0, 3.1), – | 0 of 118, 0.0 | (0.0, 3.1), – | 0 of 118, 0.0 | (0.0, 3.1), – |

* p-values of exact χ^2 -test, exposed subgroup compared to control

1
2
3
4
5
6
7
8 **Prevalence of Antibodies to Swine Influenza Viruses in Humans**
9 **with Occupational Exposure to Pigs, Thuringia, Germany, 2008-2009**
10
11
12
13

14
15
16 Andi Krumbholz¹,
17 Jeannette Lange¹,
18 Ralf Dürrwald²,
19 Heike Hoyer³,
20 Stefan Bengsch⁴,
21 Peter Wutzler¹,
22 Roland Zell^{1*}
23
24
25
26

27 ¹ Institut für Virologie und Antivirale Therapie, Universitätsklinikum Jena, Germany

28 ² IDT Biologika GmbH, Dessau-Rosslau, Germany

29 ³ Institut für Medizinische Statistik und Dokumentation, Universitätsklinikum Jena, Germany

30 ⁴ Institut für Transfusionsmedizin, Universitätsklinikum Jena, Germany
31
32
33
34
35
36
37
38

39 running title: Prevalence of antibodies to swine influenza viruses in exposed humans
40
41
42

43 * Correspondence to: Roland Zell, PhD

44 Institut für Virologie und Antivirale Therapie

45 Hans Knöll Str. 2

46 D-07745 Jena

47 Germany

48 phone: +49 3641 9395721

49 fax: +49 3641 939732

50 Roland.Zell@med.uni-jena.de
51
52
53
54
55
56
57
58
59
60

ABSTRACT

The Eurasian lineages of swine influenza viruses are different genetically from classical swine H1N1 influenza viruses and comprise avian-like H1N1 and human-like H1N2 and H3N2 subtypes. Although sporadic isolation of such viruses from human specimens has been reported, the prevalence of human infections is not known. In the present study, the seroprevalence against Eurasian swine influenza viruses was investigated. Sera were collected in Thuringia, Germany, from December 2007 to April 2009. The study group comprised 118 professionals with occupational exposure to pigs (50 pig slaughterers/meat inspectors, 46 pig farmers, 22 veterinarians caring for pig herds). The control group included 118 age- and gender-matched blood donors from Thuringia. As a result, 18 sera of the study group were identified with raised hemagglutination-inhibition titers against a panel of nine swine influenza viruses (three strains/subtype). For 17/18 sera this finding was confirmed in the neutralisation assay. For 11/18 sera the raise of titers was significant, i.e., a fourfold increase of hemagglutination-inhibition titers was observed. No gender-specific bias of the high titer sera was observed. Twelve sera of the control group showed increased hemagglutination-inhibition titers against swine influenza viruses. Hemagglutination-inhibition titers of 2/12 control sera were raised fourfold but did not exhibit a significant increase of neutralisation titers. All increased hemagglutination-inhibition titers of the control group may be explained by cross-reactivity with seasonal influenza virus strains, as all these sera also reacted with human strains.

Keywords: porcine influenza virus, zoonotic infection, virus neutralisation assay, hemagglutination-inhibition assay, occupational exposure

INTRODUCTION

Influenza A virus (FLUAV) of the genus *Influenza virus A*, family *Orthomyxoviridae*, is an important human and animal pathogen. The FLUAV host spectrum includes birds, pigs, humans and some other mammalian species. Sixteen hemagglutinin (HA) and nine neuraminidase (NA) genes allow the formation of up to 144 different subtypes, of which at least 110 have been described in aquatic birds, the main reservoir hosts. FLUAVs circulating in humans comprise the H1N1 and H3N2 subtypes and are the causative agents of seasonal influenza. Apart from seasonal influenza, occasional zoonotic infections of humans occur. Such infections may have a great impact on human health and bear the potential of a pandemic. Infections of humans with highly pathogenic avian H5N1 influenza viruses [Peiris et al., 2004; Subbarao et al., 1998] or a new pandemic swine-origin H1N1 influenza virus [Centers for Disease Control and Prevention, 2009; Novel Swine-Origin Influenza A (H1N1) Virus investigation Team, 2009] may serve as recent examples. Swine-to-human transmissions of classical swine H1N1 influenza viruses were first observed in Czechoslovakia in the 1950s [Kluska et al., 1961]. Since then, sporadic infections were demonstrated repeatedly by virus isolation in the United States, Europe and the Asian part of the former Soviet Union [reviewed in Myers et al., 2007]. After 1997, novel triple reassortant swine influenza viruses of the H3N2, H1N2, H2N3, H3N1, and H1N1 subtypes emerged in the pig population of the USA and Canada with gene segments of classical swine, avian and human viruses [Olsen, 2002]. Recently, several of these reassortants have been isolated from human patients [Shinde et al. 2009].

Eurasian swine influenza A viruses (swFLUAVs) belong to genetic lineages different from the American swFLUAVs. In Europe, porcine H1N1 strains isolated since 1979 are 'avian-like' as all segments derived from an avian virus [Pensaert et al., 1981; Witte et al., 1981]. In 1984, reassortment of an avian-like H1N1 swFLUAV and a human A/Port Chalmers/1/73-like virus yielded a so-called 'human-like' swine H3N2 strain with the HA and NA genes originating from the human virus and all segments encoding the internal proteins still being avian-like [Castrucci et al., 1993]. Furthermore, a 'human-like' swine H1N2 triple reassortant emerged in 1994 after reassortment of an European

1
2
3 swFLUAV with human H1N1 and H3N2 strains [Brown et al., 1995]. Although European swFLUAVs
4
5 and reassortant progeny strains also emerged in Hong Kong [Gregory et al., 2003; Smith et al., 2009]
6
7 and other Asian countries [Komadina et al., 2007], they became prevalent only in the European pig
8
9 population. There, they replaced the former classical swine strains. Seven cases of human infection with
10
11 the Eurasian H1N1 and H3N2 swFLUAVs have been reported so far [Adiego Sancho et al., 2009; Claas
12
13 et al., 1994; Gregory et al., 2001; Gregory et al. 2003; Rimmelzwaan et al., 2001; Schweiger et al.,
14
15 2008].
16
17
18

19
20 Recently, novel genotypes of zoonotic swFLUAVs emerged after reassortment of Eurasian and
21
22 North American swFLUAVs: (i) Strains isolated in Thailand and the Philippines demonstrate the
23
24 reassortment of classical swine viruses or North American triple reassortants (HA donor) with Eurasian
25
26 H1N1, H1N2 and H3N2 swFLUAVs (donor of NA and internal genes) [Chutinimitkul et al., 2008;
27
28 Komadina et al., 2007]. (ii) Another novel genotype, which emerged in Mexico, comprises the PB2,
29
30 PB1, PA, HA, NP and NS segments of a North American triple reassortant and the NA and MP
31
32 segments of an Eurasian swFLUAV [Novel Swine-Origin Influenza A (H1N1) Virus Investigation
33
34 Team, 2009].
35
36
37

38
39 It appears that zoonotic infections with the Eurasian swFLUAVs cause a benign disease with mild
40
41 influenza-like symptoms whereas infections with classical swine strains may lead to more serious
42
43 symptoms. Few fatalities after infections with the latter viruses were reported [reviewed in Myers et al.,
44
45 2007]. A recent study conducted in the United States revealed an increased risk of infection among pig
46
47 farm workers, veterinarians and slaughterers [Myers et al., 2006]. Despite repeated isolation of Eurasian
48
49 swFLUAVs from human specimens, the prevalence of zoonotic infections in Europe is largely unknown.
50
51 The prevalence of antibodies directed against the Eurasian swFLUAVs in probands from Thuringia,
52
53 Germany, with occupational exposure to pigs, was determined in this study.
54
55
56
57
58
59
60

MATERIAL AND METHODS

Experimental Design of the Study

In order to determine the prevalence of antibodies against swine influenza viruses in the blood of professionals with occupational exposure to pigs (exposed study group), a two-step approach was chosen. Firstly, sera from pig farm workers, pig slaughterers/meat inspectors and veterinarians from Thuringia, Germany, were assayed by the hemagglutination-inhibition (HI) test against swFLUAVs of the subtypes H1N1, H1N2 and H3N2. These subtypes are circulating at present in the European pig population. The participants of the study group were selected at random. As a control, sera from a group of age- and gender-matched blood donors who had no known contact to pigs were included in the study (unexposed control group). Of each prevalent swFLUAV subtype, three strains were included in the HI test. Possible cross-reactions with seasonal influenza viruses were examined by inclusion of three recent human strains [A/New Caledonia/20/1999 (H1N1), A/Berlin/1/2003 (H3N2), A/Baden-Württemberg/20/2003 (H1N2)] in the HI assays. In addition, all sera were tested against A/Port Chalmers/1/1973 (H3N2) and A/Chile/1/1983 (H1N1). Finally, a NP-specific ELISA (NovaTec, Dietzenbach, Germany) and a HA-specific ELISA (Virotech, Rüsselsheim, Germany) were conducted to monitor influenza the history of each serum. In the second step, sera with geometric mean titers of hemagglutination-inhibiting antibodies ≥ 80 and/or fourfold increase in HI titers against swine influenza viruses, were also assayed by the neutralisation test (NT) against porcine and human strains to confirm the HI results.

Study Group and Controls

The seroprevalence study was conducted from December, 2007 to April, 2009 in Thuringia, Germany. The study group (total $n=118$) included (i) 46 pig farmers, (ii) 50 slaughterers and meat inspectors who primarily processed pigs, (iii) 22 veterinarians caring for pig herds. A control group without pig contact was included comprising 118 blood donors from Thuringia. Control subjects were

1
2
3 frequency-matched by gender and age (<40 years, 40 to 49 years, ≥50 years). Forty-six participants in
4
5
6 each group were female and 72 were male (Table I). Each participant was interviewed to obtain
7
8 information regarding age, work experience, average exposure to pigs per week, and influenza
9
10 vaccination history. Blood sampling and test were conducted in compliance with the Declaration of
11
12 Helsinki. The experiments were approved by the Ethics Committee of the Jena University Hospital
13
14 (reference number 2092-08/07). Written informed consent was obtained from of each participant.
15
16
17

18 19 20 **Viruses**

21
22 The following nine viruses were used: (i) from the Federal Research Institute for Risk Assessment,
23
24 Berlin, Germany: A/swine/Belzig/2/2001 (H1N1), (ii) from IDT Biologika GmbH, Dessau-Rosslau,
25
26 Germany: A/swine/Haselünne/IDT2617/2003 (H1N1), A/swine/Bad Griesbach/IDT5604/2006 (H1N1),
27
28 A/swine/Bakum/1832/2000 (H1N2), A/swine/Waltersdorf/IDT2527/2003 (H1N2),
29
30 A/swine/Gudensberg/IDT2930/2004 (H1N2), A/swine/Bakum/IDT1769/2003 (H3N2),
31
32 A/swine/Bissendorf/IDT1864/2003 (H3N2), A/swine/Herzlake/IDT5336/2006 (H3N2), A/Port
33
34 Chalmers/1/1973 (H3N2), (iii) the Robert Koch Institute, Berlin, Germany: A/New Caledonia/20/1999
35
36 (H1N1), A/Baden Württemberg/20/2003 (H1N2), A/Berlin/1/2003 (H3N2), (iv) the
37
38 Landesgesundheitsamt Niedersachsen, Hannover, Germany: A/Chile/1/1983 (H1N1). All porcine strains
39
40 were sequenced completely to assure their membership to the Eurasian lineages of swFLUAVs. Three
41
42 strains [A/swine/Haselünne/IDT2617/2003 (H1N1), A/swine/Bakum/1832/2000 (H1N2),
43
44 A/swine/Bakum/1769/2003 (H3N2)] are components of a new trivalent swine influenza vaccine. The
45
46 viruses were either passaged in embryonated hens eggs or in Madin Darby Canine Kidney (MDCK) cells
47
48 (ATCC CCL-34). Cells were propagated in Eagle Minimum Essential medium (EMEM) supplemented
49
50 with 10% (v/v) fetal bovine serum, 100 units/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine,
51
52 1.3% (v/v) sodium bicarbonate. Virus titers were determined by the 50% tissue culture infectious dose
53
54 (TCID₅₀) assay according to Reed and Munch.
55
56
57
58
59
60

Hemagglutination-Inhibition (HI) Assay

For the HI assay, pretreatment of sera was carried out as follows: (i) pretreatment with neuraminidase (SIGMA, N-3001) 1:40 diluted with 0.9% (w/v) sodium chloride for 14–18 hours at 37 °C, (ii) addition of 1.5% (w/v) sodium citrate and inactivation for 30 min at 56 °C, (iii) adsorption of sera with red blood cells for one hour at 4–8 °C. Serial twofold dilution of sera was carried out in microtiter plates. Standardised antigen (with a hemagglutination titer of 8 hemagglutinating units of each antigen investigated) was then added to 100 µl serum dilution. The mixture was incubated at 20–25 °C for 45 min and a standardised solution (0.5%) of red blood cells was added. The reaction was again incubated at 20–25 °C for 30 min. Negative and positive controls as well as sera controls and red blood cell control were included. Finally, the HI titers (the highest dilution of serum that inhibited virus-induced hemagglutination) were recorded. HI assay was carried out three times on each virus, and the geometric mean HI titers were calculated. Chicken red blood cells were used for all influenza viruses except the recent human H3N2 strain A/Berlin/1/2003; for this strain turkey red blood cells were used. A high titer serum showed a HI titer ≥ 80 and/or a fourfold increase when compared to the group-specific geometric mean titer. In addition, a box plot analysis was performed. High titer sera exceeded the interquartile range at least 1.5-fold (data not shown).

Neutralisation Assay

Twofold serial dilutions of sera were prepared for the neutralisation test. All virus strains to be investigated were adjusted to 100 TCID₅₀/50 µl. Fifty microliters of these working dilutions of virus were mixed with 100 µl of serum dilutions and incubated one hour at 37 °C. MDCK monolayers in microtiter plates were then infected with the neutralisation mixtures. Trypsin [porcine, gamma-irradiated (Sigma), final concentration 4 BAEE units/ml medium] was added to the medium and read after 24 hours. After 48 hours of incubation (37 °C and 5% CO₂), cells were fixed with 4% formalin (4–8 °C) and stained with crystal violet. Finally the ND₅₀ (highest dilution of serum which neutralised the virus strain) was calculated. The neutralisation assay was performed two times with each virus strain, and

1
2
3 geometric mean neutralisation titers were calculated. Geometric mean neutralisation titers $\geq 1:80$ were
4
5 scored positive in order to obtain higher values of specificities.
6
7
8
9

10 **Influenza Virus-Specific ELISA**

11
12 Two commercial influenza virus-specific ELISAs were used to analyse the influenza history of the
13 exposed study group and the control group. A nucleoprotein (NP) specific ELISA based on
14
15 A/Texas/1/1977 (H3N2) and B/Hong Kong/5/1972 was obtained from NovaTec (Dietzenbach,
16
17 Germany). An IgG-specific ELISA directed against the hemagglutinins of the 2006/07 season
18
19 (A/Solomon Islands/03/06-like H1N1 and A/Wisconsin/67/05-like H3N2 viruses) was obtained from
20
21 Virotech (Rüsselsheim, Germany). Both assays were conducted as described by the manufacturers. A
22
23 serum was considered positive when the assay yielded values greater 11 ELISA units [ELISA unit of
24
25 proband serum = $10 \times (\text{OD}_{450} \text{ proband serum} / \text{OD}_{450} \text{ cut-off control})$]. Sera yielding < 9 ELISA units were
26
27 considered negative; sera yielding 9.0-11.0 ELISA units were considered indeterminate.
28
29
30
31
32
33
34
35
36

37 **Statistical Analysis of Serological Data**

38
39 According to reported data [Myers et al., 2006] a seroprevalence of 10% to 20% was expected in the
40 exposed subjects. For this pilot study, a stratified sampling of about 40 subjects selected at random per
41 occupational subgroup was planned. A two-sided 95% confidence interval (CI) would extend 9% to 12%
42
43 from the observed prevalence.
44
45
46
47

48 Data were displayed by geometric means and geometric standard deviations (GSD) as appropriate.
49
50 Group-specific prevalences were estimated with exact 95% CI assuming a binomial distribution. If the
51 global χ^2 -test of homogeneity could be rejected for a subtype at $\alpha=0.05$ seroprevalences of
52
53 occupational subgroups were compared to controls subsequently. A p-value of < 0.05 was considered to
54
55 be statistically significant. SAS V0-2 and SPSS 15.0 were used for analysis.
56
57
58
59
60

RESULTS

Characteristics of the Study Group and Controls

The study group (exposed) and the control group (unexposed) each consisted of 118 participants. The composition of the control group was chosen to match the study group in terms of gender and age (Table I). The ratio of male and female subjects was 72 (61%) to 46 (39%) in both groups. The mean age was 44.6 years (SD=10.7) in the exposed and 43.8 years (SD=11.8) in the unexposed subjects. Analysis of the questionnaire revealed no significantly higher proportion of influenza vaccination in the control group. Sixty-five of 118 participants (55.1%) of the control group vs. 52 of 118 participants (44.1%) of the study group remembered at least one vaccination ($p=0.059$, 1-sided χ^2 -test). One hundred and thirteen of 117 sera of the exposed group and 116 of 118 sera of the control group exhibited a previous influenza virus infection using a NP-specific ELISA. A HA-specific ELISA directed against virus strains of the 2006/2007 season showed 48.7 % positive sera of the exposed group and 50.1 % of the control group. The results of the NP- and HA-specific ELISAs indicate that both groups were comparable regarding previous influenza virus infections (NP ELISA: $p=0.402$, HA ELISA: $p=0.744$).

HI Assays

HI assays were performed to identify sera with increased antibody titers to swFLUAVs. For each of the three swFLUAV subtypes, three strains were included in the HI assays (**H1N1**: A/swine/Belzig/2/2001, A/swine/Haselünne/IDT2617/2003, A/swine/Bad Griesbach/IDT5604/2006, **H1N2**: A/swine/Bakum/1832/2000, A/swine/Waltersdorf/IDT2527/2003, A/swine/Gudensberg/IDT2930/2004, **H3N2**: A/swine/Bakum/IDT1769/2003, A/swine/Bissendorf/IDT1864/2003, A/swine/Herzlake/IDT5336/2006). The geometric mean HI titers of the study group were 10.34 (GSD \pm 12.08) for the H1N1 strains, 29.21 (GSD \pm 27.14) for the H1N2 strains and 24.68 (GSD \pm 33.14) for the H3N2 strains. Eighteen conspicuous proband sera of the exposed group (15.3%) were identified (Table II), 16 of whom had HI titers \geq 80; two sera (S #47, V #10) were

1
2
3 identified as outliers in the box plot (data not shown). Six to 12 months after sampling, those participants
4 who had conspicuous sera were asked for a second blood sample. Thirteen of 18 participants agreed and
5 the follow-up sera were re-investigated. All previous HI results were confirmed and the titers of the
6 majority of the follow-up sera exceeded the previous HI titers (data not shown).
7
8
9

10
11
12 The geometric mean HI titers of the control group were 8.71 (GSD \pm 6.45) (H1N1), 26.31 (GSD
13 \pm 23.26) (H1N2) and 23.98 (GSD \pm 23.23) (H3N2). Twelve high titer sera were observed in the control
14 group (Table II). Comparison of the HI results of the study group and the unexposed control group
15 revealed no significant differences in the distribution of the HI titers (Table III) suggesting that this
16 comparison may not be suited to distinguish swFLUAV infection and previous exposure to seasonal
17 influenza. Therefore, neutralisation assays were performed with the 30 high titer sera compiled in Table
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

II.

Neutralisation Assays

Neutralisation assays revealed that 17/18 sera of the study group with raised HI antibody titers also had elevated neutralising antibody titers against at least one of the nine tested virus strains (Table II). A serum was scored positive for the respective strain if the reciprocal of the geometric mean titer was \geq 80. Only the swH1N2-positive result of slaughterer #2 could not be confirmed by the NT. The NT titers against swH3N2 of sixteen sera exceeded those against huH3N2 indicating previous exposure to swH3N2. Likewise, 7 swH1N2 and 2 swH1N1 titers of the exposed group exceeded the titers of human reference strains. With the exception of C #115, the high HI titers of the control sera could not be confirmed in the NT. Serum C #115 also showed high HI and NT titers against the human H1 strains. One blood sample (S #8) did not yield sufficient serum for the neutralisation tests with the human viruses.

Prevalence

1
2
3 Sixteen sera with HI and NT titers against swFLUAVs were identified in the exposed group (Table
4 II). According to the stratified sampling, the seroprevalences of antibodies against the three swFLUAV
5 subtypes were estimated for the three subgroups of exposed subjects and for the unexposed controls. The
6 data are shown in Table IV.
7
8
9
10
11

12 The lowest prevalence of 0% in veterinarians, 0% in pig farmers and 4% in slaughterers was for
13 H1N1. The prevalence for H1N2 ranged from 4.3% (pig farmers) to 9.1% (veterinarians) and those of
14 H3N2 ranged from 8.7% (pig farmers) to 22.7% (veterinarians).
15
16
17
18
19
20
21
22
23

24 DISCUSSION

25
26
27
28
29 After their first appearance in Germany and Belgium in 1979, avian-like H1N1 swFLUAVs spread
30 rapidly spread throughout Europe. Within 15 years, novel strains emerged after reassortment with human
31 H3N2 and H1N1 viruses and replaced the classical swine H1N1 viruses. The earliest German human-
32 like H3N2 and H1N2 strains of the Eurasian lineages of swFLUAVs are documented 1982 and 2000,
33 respectively [Schrader und Süß, 2003, 2004]. All three Eurasian lineages have the potential to cause
34 zoonotic human infection and this has been demonstrated by the isolation of several virus strains from
35 human specimens in recent years [Adiego Sancho et al., 2009; Claas et al. 1994; Gregory et al., 2001;
36 Gregory et al., 2002; Rimmelzwaan et al. 2001; Schweiger et al. 2008]. As sporadic virus isolations from
37 humans provide no indication on the actual number of zoonotic infections, the prevalence of antibodies
38 against swFLUAVs in humans with occupational exposure to pigs in Thuringia, Germany was
39 determined. The German Federal State of Thuringia has an area of 16,251 square kilometres and some
40 2.3 million inhabitants. With approximately 1,400 pig farms and 765,000 pigs (mean pig herd size: 544.1
41 pigs), it has a small pig population of 2.8% of German pigs compared to other German States such as
42 Northrhine Westphalia (12,900 pig farms, 6,358,100 pigs, mean pig herd size: 493.6 pigs; 23.4% of
43 German pigs) or Lower Saxony (14,300 pig farms, 8,201,700 pigs, mean pig herd size: 572.6 pigs;
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 30.2% of German pigs) (source: www.destatis.de, 3 May 2007). In the present study, the pig
4
5
6 slaughterers/meat inspectors of four of eight Thuringian slaughterhouses were tested. These persons
7
8 represent approximately 50% of the Thuringian pig slaughterers/meat inspectors. In addition, 5.1% of
9
10 the Thuringian veterinarians caring for pig herds and approximately 0.9% of Thuringian pig farm
11
12 workers involved in pig fattening were included. The participants of the exposed group were selected at
13
14 random from the telephone directory and no evidence was found for biased sampling. Most participants
15
16 of the study group stated numerous direct contacts to pigs (at least twice a week). Only veterinarian #1
17
18 and pig farmer #41 specified 1 contact per week. The control group was comparable to the study group
19
20 regarding mean age, gender and influenza history but had no known exposure to pigs. Twelve subjects of
21
22 this group exhibited high HI antibody titers (swH1N2: 7/12, swH3N2: 5/12). Only two of them (C #88,
23
24 C #119) had a fourfold increase in the HI titer and only one control serum (C #115) had both a 3-fold
25
26 raised HI titer and a reciprocal geometric mean NT titer of 89.9. However, C #115 serum also showed
27
28 elevated HI and NT titers against human H1N1 and H1N2 viruses (Table II) suggesting that cross-
29
30 reactivity after previous exposure to seasonal virus may be a plausible explanation for its reaction with
31
32 swH1N2. All high titer control sera which reacted with swH1N2 had also elevated antibody titers against
33
34 human H1 strains (compare Table II). Two of the five control sera that reacted with swH3N2 had also
35
36 high HI or NT titers against huH3N2 (Table II). Presuming random sampling, the proportions of sera
37
38 scored positive against swFLUAVs were calculated. Dependent on profession and virus subtype
39
40 different prevalences were observed (Table IV). However, the estimated prevalence of the swH1N1
41
42 subtype was not significant since only two sera were positive against these antigens. In Germany,
43
44 swH1N1 strains comprise approximately 10-15% of the swFLUAV isolates. In addition, swH1N1 causes
45
46 diseases in the pig with milder symptoms and replicates at lower titers in the lungs compared to the
47
48 swH1N2 and swH3N2 subtypes (Ralf Dürrwald, unpublished results). Therefore, exposure of the study
49
50 group to swH1N1 viruses might have been lower in recent years than to the other swFLUAV subtypes.
51
52 The swH1N2 and swH3N2 lineages have surface proteins derived from seasonal influenza viruses. Due
53
54
55
56
57
58
59
60

1
2
3 to a better adaptation of these surface proteins to the human host, it can be assumed that zoonotic
4
5 infections of humans are caused preferentially by the human-like swFLUAVs.
6
7

8 Zoonotic influenza virus infections appear to be not gender-specific; the observed bias of positive
9
10 sera of male slaughterers is due to the imbalance of male and female employees working in this
11
12 profession. All female employees of this proband subgroup worked as meat inspectors. Like the male
13
14 meat inspectors, none of their sera reacted with swFLUAVs. This observation suggests that pig
15
16 slaughtering itself is a risky activity whereas downstream processes such as meat inspection have a
17
18 considerable lower risk of infection.
19
20
21

22 In the present study, virus neutralisation assays distinguished clearly between Eurasian swFLUAVs
23
24 and those human seasonal influenza virus strains which were used for control (Table II). Some high titer
25
26 study group sera (e.g., S #21, S #24, PF #22, V #10, V #14, V #18) showed little or no cross-reaction
27
28 with the human control virus strains. Other study group sera (e.g. S #22, PF #16, PF #18, V #1) reacted
29
30 with both porcine and human strains. This finding may be explained with repeated exposure to human
31
32 and porcine viruses. An alternative explanation could be the assumption of significant cross-reaction.
33
34 Some cross-reaction of the sera of control subjects with swine H3N2 triple reassortants was observed in
35
36 a previous study conducted by Myers et al. [2006]. In the present study, however, conspicuous sera of
37
38 the study group and the control group differ considerably indicating that cross-reaction is not a major
39
40 problem. Only serum PF #18 showed antibodies against swH1N2, swH3N2 and the three human strains
41
42 suggesting cross-reactivity. This serum was negative for swH3N2 as the HI and NT titers against
43
44 huH3N2 were considerably higher. Future studies should include more human reference strains to
45
46 address this question in more detail.
47
48
49
50
51
52

53 Recent studies provided evidence that humans with occupational exposure to pigs have experienced
54
55 zoonotic influenza virus infections [Myers et al. 2006; Shinde et al. 2009]. The present study extends
56
57 these previous observations for Thuringian employees even though American and Eurasian swFLUAVs
58
59 evolved from genetically distinct origins. The zoonotic potential of animal influenza viruses led to the
60
recommendation that workers with close contact to pigs and poultry should receive the annual human

1
2
3 influenza vaccine [Gray et al., 2007]. It was reasoned that professionals with exposure to pigs and
4
5 poultry could serve as a human bridging population for both human-to-animal and animal-to-human
6
7 infections [Gray et al., 2007]. Annual influenza vaccination would decrease the threat of double
8
9 infections of humans and reduce the risk of transmission of human virus strains to the pig population.
10
11 This minimises the risk of concomitant double infections of swine with human and porcine virus strains
12
13 and would lead to lessened reassortments and a reduced risk of generation of novel strains with
14
15 pandemic potential. In view of the special situation caused by the pandemic A/H1N1 2009 virus, this
16
17 recommendation should be implemented.
18
19
20
21

22 23 24 25 26 27 **ACKNOWLEDGMENT**

28
29 We are indebted to Dr. Brunhilde Schweiger, *Robert Koch Institute*, Berlin, Germany, Dr. Rolf
30
31 Heckler, Landesgesundheitsamt Niedersachsen, Hannover, Germany, and Dr. Jochen Süß, Federal
32
33 Research Institute for Risk Assessment, Berlin, Germany, for the gift of strains. We further thank Dr.
34
35 Karsten Donat, Tierseuchenkasse Thüringen, and Karin Siedhoff, Landestierärztekammer Thüringen.
36
37

38
39 This study was supported in part by grants of the Interdisziplinäres Zentrum für Klinische Forschung
40
41 (Jena University Hospital), the Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. and the Deutsche
42
43 Vereinigung zur Bekämpfung der Viruskrankheiten e.V. awarded to A.K.
44
45
46
47

48 49 50 51 52 **REFERENCES**

- 53 Adiego Sancho B, Omenaca Teres M, Martinez Cuenca S, Rodrigo Val P, Sanchez Villanueva P, Casas
54
55 I, Pozo F, Perez Brena P. 2009. Human case of swine influenza A (H1N1), Aragon, Spain,
56
57 November 2008. *Eurosurveillance* 14:1–2.
- 58
59 Brown IH, Chakraverty P, Harris PA, Alexander DJ. 1995. Disease outbreaks in pigs in Great Britain
60
due to an influenza A virus of H1N2 subtype. *Vet Rec* 136:328–329.

- 1
2
3 Castrucci MR, Donatelli I, Sidoli L, Barigazzi G, Kawaoka Y, Webster RG. 1993. Genetic reassortment
4 between avian and human influenza A viruses in Italian pigs. *Virology* 193:503–506.
5
6
7
8 Centers for Disease Control and Prevention. 2009. Swine Influenza A (H1N1) infection in two children
9 – Southern California, March – April 2009. *Morb Mort Weekly Rep* 58:400–402.
10
11
12 Chutinimitkul S, Thippamom N, Damrongwatanapokin S, Payungporn S, Thanawongnuwech R,
13 Amonsin A, Boonsuk P, Sreta D, Bunpong N, Tantilertcharoen R, Chamnanpood P, Parchariyanon
14 S, Theamboonlers A, Poovorawan Y. 2008. Genetic characterization of H1N1, H1N2 and H3N2
15 swine influenza virus in Thailand. *Arch Virol* 153:1049–1056.
16
17
18
19
20
21
22 Claas ECJ, Kawaoka Y, De Jong JC, Masurel N, Webster RG. 1994. Infection of children with avian-
23 human reassortant influenza virus from pigs in Europe. *Virology* 204:453–457.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Gray GC, Trampel DW, Roth JA. 2007. Pandemic influenza planning: shouldn't swine and poultry workers be included? *Vaccine* 25:4376–4381.
- Gregory V, Lim W, Cameron K, Bennett M, Marozin S, Klimov A, Hall H, Cox N, Hay A, Lin YP. 2001. Infection of a child in Hong Kong by an influenza A H3N2 virus closely related to viruses circulating in European pigs. *J Gen Virol* 82:1397–1406.
- Gregory V, Bennett M, Thomas Y, Kaiser L, Wunderli W, Matter H, Hay A, Lin YP. 2003. Human infection by a swine influenza A (H1N1) virus in Switzerland. *Arch Virol* 148:793–802.
- Kluska V, Macku M, Mensik J. 1961. Demonstration of antibodies against swine influenza viruses in man [in Czech]. *Cesk Pediatr* 16:408–414.
- Komadina N, Roque V, Thawatsupha P, Rimando-Magalong J, Waicharoen S, Bomasang E, Sawanpanyalert P, Rivera M, Iannello P, Hur AC, Barr IG. 2007. Genetic analysis of two influenza A (H1) swine viruses isolated from humans in Thailand and the Philippines. *Virus Genes* 35:161–165.
- Myers KP, Olsen CW, Gray GC. 2007. Cases of swine influenza in humans: a review of the literature. *Clin Infect Dis* 44:1084–1088.

- 1
2
3 Myers KP, Olsen CW, Setterquist SF, Capuano AW, Donham KJ, Thacker EL, Merchant JA, Gray GC.
4
5 2006. Are swine workers in the United States at increased risk of infection with zoonotic influenza
6
7 virus? *Clin Infect Dis* 42:14–20.
8
9
10 Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. 2009. Emergence of a novel swine-
11
12 origin influenza A (H1N1) virus in humans. *N Engl J Med* 360:2605–2615.
13
14
15 Olsen CW. 2002. The emergence of novel swine influenza viruses in North America. *Virus Res* 85:199–
16
17 210.
18
19
20 Peiris M, Yu WC, Leung CW, Cheung CY, Ng WF, Ng TK, Chan KH, Lai ST, Lim WL, Yuen KY,
21
22 Guan Y. 2004. Re-emergence of fatal human influenza A subtype H5N1 disease. *Lancet* 363:617–
23
24 619.
25
26
27 Pensaert M, Ottis K, Vandeputte J, Kaplan MM, Bachmann PA. 1981. Evidence for the natural
28
29 transmission of influenza A virus from wild ducks to swine and its potential importance for man.
30
31 *Bull WHO* 59:75–78.
32
33
34 Rimmelzwaan GF, de Jong JC, Bestebroer TM, van Loon AM, Claas ECJ, Fouchier RAM, Osterhaus
35
36 ADME. 2001. Antigenic and genetic characterization of swine influenza A (H1N1) viruses isolated
37
38 from pneumonia patients in the Netherlands. *Virology* 282:301–308.
39
40
41 Schrader C, Süß J. 2003. Genetic characterization of a porcine H1N2 influenza virus strain isolated in
42
43 Germany. *Intervirology* 46:66–70.
44
45
46 Schrader C, Süß J. 2004. Molecular epidemiology of porcine H3N2 influenza A viruses isolated in
47
48 Germany between 1982 and 2001. *Intervirology* 47:72–77.
49
50
51 Schweiger B, Heckler R, Biere B. 2008. Characterization of a porcine influenzavirus isolated from a
52
53 human sample. In: Programme and Abstracts; Heidelberg; March 5–8, 2008; Abstract CLV2.
54
55 Heidelberg: 18th Annual Meeting Gesellschaft für Virologie.
56
57
58 Shinde V, Bridges CB, Uyeki TM, Shu B, Balish A, Xu X, Lindstrom S, Gubareva LV, Deyde V, Garten
59
60 RJ, Harris M, Gerber S, Vagasky S, Smith F, Pascoe N, Martin K, Dufficy D, Ritger K, Conover

- 1
2
3 C, Quinlisk P, Klimov A, Bresee JS, Finelli L. 2009. Triple-reassortant swine influenza A (H1) in
4 humans in the United States, 2005-2009. *N Engl J Med* 360:2616–2625.
5
6
7
8 Smith GJD, Vijaykrishna D, Bahl J, Lycett SJ, Worobey M, Pybus OG, Ma SK, Cheung CL, Raghwani
9 J, Bhatt S, Peiris JSM, Guan Y, Rambaut A. 2009. Origins and evolutionary genomics of the 2009
10 swine-origin H1N1 influenza A epidemic. *Nature* 459:1122–1125.
11
12
13
14 Subbarao K, Klimow A, Katz J, Regnery H, Lim W, Hall H, Perdue M, Swayne D, Bender C, Huang J,
15 Hemphill M, Rowe T, Shaw M, Xu X, Fukuda K, Cox N. 1998. Characterization of an avian
16 influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. *Science* 279:393–
17 396.
18
19
20
21
22
23
24 Witte KK, Nienhoff H, Ernst H, Schmidt U, Prager D. 1981. The 1st appearance of swine influenza in
25 pig herds in the Federal-Republic-of-Germany [in German]. *Tierärztliche Umschau* 36:591.
26
27
28
29 Zell R, Motzke S, Krumbholz A, Wutzler P, Herwig V, Dürrwald R. 2008. Novel reassortant of swine
30 influenza H1N2 virus in Germany. *J Gen Virol* 89:271–276.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60